Literature DB >> 2872058

The pharmacokinetics after intravenous and oral administration in man of the alpha 2-adrenoreceptor antagonist idazoxan (RX781094).

N C Muir, J G Lloyd-Jones, J D Nichols, J M Clifford.   

Abstract

A high performance liquid chromatographic method was developed for the quantitative determination of idazoxan in plasma. The assay was used to study the disposition of the drug after intravenous infusion and oral administration to five normal subjects. After i.v. administration the kinetics could be described by a two compartment model with a mean elimination half life of 4.20 h. The mean calculated volume of distribution during the elimination phase was 3.20 l/kg-1 and the mean plasma clearance was 824 ml min-1. After oral administration a lag period before onset of absorption was observed in all five volunteers, the plasma levels declining monoexponentially from the peak concentration with a mean elimination half life of 5.58 h. The absolute availability varied between 26% and 41% with a mean value of 34%. In-vitro measurements produced a blood/plasma ratio of 1.3 for idazoxan.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2872058     DOI: 10.1007/bf00615972

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  2 in total

1.  Influence of first-pass effect on availability of drugs on oral administration.

Authors:  M Gibaldi; R N Boyes; S Feldman
Journal:  J Pharm Sci       Date:  1971-09       Impact factor: 3.534

2.  RX781094, a new potent alpha 2 adrenoceptor antagonist. In vivo and in vitro studies in the rabbit.

Authors:  J A Hannah; C A Hamilton; J L Reid
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-04       Impact factor: 3.000

  2 in total
  1 in total

1.  Effects of idazoxan on alcohol pharmacokinetics and intoxication: a preliminary human laboratory study.

Authors:  Carolina L Haass-Koffler; Lorenzo Leggio; Dena Davidson; Robert M Swift
Journal:  Alcohol Clin Exp Res       Date:  2015-04       Impact factor: 3.455

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.